nVision Medical Company

Acquired by Boston Scientific. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes.

Headquarters: San Bruno, California, United States
Last Funding Type: Series B
Investors Number: 9
Last Funding Date: 2016-07-21
Employee Number: 1-10
Total Funding: $16,405,000
Founded Date: 01-01-2009
Estimated Revenue: $1M to $10M
Industry: General Health Care
Funding Status: M&A